WHO PURGES HEAD OF AFRICAN OFFICE, HIV/AIDS STAFFER ELECTED TO PUSH MASS EBOLA VACCINATION AGENDA

WHO PURGES HEAD OF AFRICAN OFFICE, HIV/AIDS STAFFER ELECTED TO PUSH MASS EBOLA VACCINATION AGENDA

November 5, 2014
http://birdflu666.wordpress.com/

“The World Health Organization (WHO) elected a longtime veteran of the U.N. agency as the head of its Africa office on Wednesday, amid criticism of its handling of the Ebola epidemic in West Africa,” reports Reuters.

http://www.reuters.com/article/2014/11/05/us-health-ebola-who-idUSKBN0IP1MW20141105

Botswana’s Dr. Matshidiso Rebecca Moeti, a former deputy director of the WHO’s Africa office (AFRO), won a secret ballot after Dr Luis Gomes was criticized by Globalists for doing too little to push the Ebola false flag epidemic forward.

Moeti was a regional adviser on the WHO’s HIV/AIDS programme and head of its Malawi office.

Botswana and ACHAP, a private public partnership headed by Themba Moeti, has received significant funding from Merck and the Bill and Melinda Gates Foundation for HIV and AIDS drugs.

From a Merck press release from 2010.

“2010 – Merck today announced the Merck Company Foundation and the Bill & Melinda Gates Foundation are committing an additional $60 million to support Botswana’s African Comprehensive HIV/AIDS Partnerships (ACHAP). Merck is known as MSD outside the US and Canada. A unique program developed with and led by the Government of Botswana, ACHAP is one of sub-Saharan Africa’s oldest, most successful public-private partnerships. With today’s pledge, the Merck Foundation and the Gates Foundation’s total cash contributions now amount to $166.5 million. Merck will also continue the donation of its HIV medicines.

Building on the successes created by its initial investment of $56.5 million nine years ago, Merck will contribute an additional $30 million over the next five years. The new funding will continue the program’s original efforts in treatment and care but also will support the second phase initiatives to meet the current treatment needs of the 137,000 Batswana (people from Botswana) living with HIV and new patients enrolled in the second phase. The second phase initiatives include: the prevention of HIV, the critical need to treat people living with HIV for tuberculosis (TB) and the sustainability of the program to allow Botswana to successfully address HIV/AIDS within its own borders.”

http://www.merck.com/corporate-responsibility/docs/FINAL_ACHAP_Release_82310.pdf

Leave a Reply